Dan Shao

Dr. Dan Shao

School of Biomedical Science and Engineering, South China University of Technology, Guangzhou, China
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2022 in Nature Reviews Materials
Verified
Journal Article
Closed access
PDF file
ZTZhaoxu Tu
Zhaoxu Tu
YZYiling Zhong
Yiling Zhong
HHHanze Hu
Hanze Hu
DSDan Shao
Dan Shao
RHRainer Haag
Rainer Haag
KLKam W Leong
Kam W Leong

28 May 2018 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
DSDan Shao
Dan Shao
Mingqiang LiMingqiang Li
Mingqiang Li
ZWZheng Wang
Zheng Wang
XZXiao Zheng
Xiao Zheng
YLYeh‐Hsing Lao
Yeh‐Hsing Lao
KLKam W Leong
Kam W Leong

29 June 2016 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
QZQinghui Zeng
Qinghui Zeng
DSDan Shao
Dan Shao
XHXu He
Xu He
ZRZhongyuan Ren
Zhongyuan Ren
WJWenyu Ji
Wenyu Ji
QLQin Li
Qin Li
Fluorescent carbon dots (CDs) with a size smaller than 10 nm, excellent biocompatibility, and low to no cytotoxicity are considered as a rising star in nanomedicine. In this report, for the first time we demonstrate that green-emitting CDs with a carboxyl-rich surface can be employed as a trackable drug delivery agent for localized cancer treatment in a mouse model. The CDs are conjugated with the cancer drug, Doxorubicin (DOX), via non-covalent bonding, utilizing the native carboxyl groups on CDs and the amine moiety on DOX molecules. The pH difference between cancer and normal cells was successfully exploited as the triggering mechanism for DOX release. Our in vivo study demonstrated that the fluorescent CDs can serve as a targeted drug delivery system for localized therapy, and the stimuli-responsive non-covalent bonding between the nanodot carrier and the drug molecule is sufficiently stable in complex biological systems. Taken together, our work provides a strategy to promote the potential clinical application of CDs in cancer theranostics.

28 January 2022 in Science Advances
Verified
Journal Article
Open access
CSChengxin Shi
Chengxin Shi
JDJianati Dawulieti
Jianati Dawulieti
FSFeiyu Shi
Feiyu Shi
CYChao Yang
Chao Yang
QQQian Qin
Qian Qin
JSJunjun She
Junjun She
A therapeutic strategy that targets multiple proinflammatory factors in inflammatory bowel disease (IBD) with minimal systemic side effects would be attractive. Here, we develop a drug-free, biodegradable nanomedicine that acts against IBD by scavenging proinflammatory cell-free DNA (cfDNA) and reactive oxygen species (ROS). Polyethylenimine (PEI) was conjugated to antioxidative diselenide-bridged mesoporous organosilica nanoparticles (MONs) to formulate nanoparticles (MON-PEI) that exhibited high cfDNA binding affinity and ROS-responsive degradation. In ulcerative colitis and Crohn’s disease mouse colitis models, orally administered MON-PEI accumulated preferentially in the inflamed colon and attenuated colonic and peritoneal inflammation by alleviating cfDNA- and ROS-mediated inflammatory responses, allowing a reduced dose frequency and ameliorating colitis even after delayed treatment. This work suggests a new nanomedicine strategy for IBD treatment.

12 September 2019 in Advanced Science
Verified
Journal Article
Open access
PDF file
ZWZheng Wang
Zheng Wang
FZFan Zhang
Fan Zhang
DSDan Shao
Dan Shao
ZCZhimin Chang
Zhimin Chang
LWLei Wang
Lei Wang
WDWen-Fei Dong
Wen-Fei Dong
Photodynamic therapy (PDT) is clinically promising in destructing primary tumors but ineffective against distant metastases. This study reports the use of immunogenic nanoparticles mediated combination of PDT and magnetic hyperthermia to synergistically augment the anti‐metastatic efficacy of immunotherapy. Janus nanobullets integrating chlorine e6 (Ce6) loaded, disulfide‐bridged mesoporous organosilica bodies with magnetic heads (M‐MONs@Ce6) are tailored for redox/pH‐triggered photosensitizer release accompanying their matrix degradation. Cancer cell membrane cloaking enables favorable tumor‐targeted accumulation and prolonged blood circulation time of M‐MONs@Ce6. The combination of PDT and magnetic hyperthermia has a strong synergy anticancer activity and simultaneously elicits a sequence of immunogenic cell death, resulting in synergistically tumor‐specific immune responses. When combined with anti‐CTLA‐4 antibody, the biomimetic and biodegradable nanoparticle enables the notable eradication of primary and deeply metastatic tumors with low systematic toxicity, thus potentially advancing the development of combined hyperthermia, PDT, and checkpoint blockade immunotherapy to combat cancer metastasis.

22 May 2019 in Advanced Science
Verified
Journal Article
Open access
PDF file
HYHuize Yan
Huize Yan
DSDan Shao
Dan Shao
YLYeh‐Hsing Lao
Yeh‐Hsing Lao
Mingqiang LiMingqiang Li
Mingqiang Li
HHHanze Hu
Hanze Hu
KLKam W Leong
Kam W Leong
Inflammation is ubiquitous in the body, triggering desirable immune response to defend against dangerous signals or instigating undesirable damage to cells and tissues to cause disease. Nanomedicine holds exciting potential in modulating inflammation. In particular, cell membranes derived from cells involved in the inflammatory process may be used to coat nanotherapeutics for effective targeted delivery to inflammatory tissues. Herein, the recent progress of rationally engineering cell membrane‐based nanotherapeutics for inflammation therapy is highlighted, and the challenges and opportunities presented in realizing the full potential of cell‐membrane coating in targeting and manipulating the inflammatory microenvironment are discussed.